Steven M Chan
Overview
Explore the profile of Steven M Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
2251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Liu A, Cathelin S, Yang Y, Dai D, Manikoth Ayyathan D, Hosseini M, et al.
Cancer Res
. 2022 Sep;
82(23):4325-4339.
PMID: 36150062
Significance: A CRISPR knockout screen identifies a mechanism of resistance to IDH inhibitors in AML involving activated STAT5 signaling, suggesting a potential strategy to improve the clinical efficacy of IDH...
12.
Cescon D, Bratman S, Chan S, Siu L
Nat Cancer
. 2022 Feb;
1(3):276-290.
PMID: 35122035
Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the capabilities of this technology as...
13.
Vanner R, Dobson S, Gan O, McLeod J, Schoof E, Grandal I, et al.
Blood Cancer Discov
. 2022 Jan;
3(1):16-31.
PMID: 35019858
Central nervous system (CNS) dissemination of B-precursor acute lymphoblastic leukemia (B-ALL) has poor prognosis and remains a therapeutic challenge. Here we performed targeted DNA sequencing as well as transcriptional and...
14.
Cathelin S, Sharon D, Subedi A, Cojocari D, Phillips D, Leverson J, et al.
Leukemia
. 2021 Nov;
36(3):869-872.
PMID: 34743189
No abstract available.
15.
Chow S, Tang K, Al-Abri M, Hall V, Tremblay-LeMay R, Rashedi I, et al.
Leuk Res
. 2021 Nov;
111:106735.
PMID: 34735933
No abstract available.
16.
Subedi A, Liu Q, Ayyathan D, Sharon D, Cathelin S, Hosseini M, et al.
Cell Stem Cell
. 2021 Jul;
28(10):1851-1867.e8.
PMID: 34293334
Current treatments for acute myeloid leukemia (AML) are often ineffective in eliminating leukemic stem cells (LSCs), which perpetuate the disease. Here, we performed a metabolic drug screen to identify LSC-specific...
17.
Chen R, Liu X, Law A, Kanfar S, Maze D, Chan S, et al.
Curr Oncol
. 2021 Mar;
28(1):128-137.
PMID: 33704181
Background: venous thromboembolism (VTE) is a well-known complication in adults with acute lymphoblastic leukemia (ALL), especially in patients treated with asparaginase (ASNase)-including regiments. However, VTE risk in adult Philadelphia-positive ALL...
18.
Abelson S, Zeng A, Nofech-Mozes I, Wang T, Ng S, Minden M, et al.
Sci Adv
. 2020 Dec;
6(50).
PMID: 33298453
Sensitive mutation detection by next-generation sequencing is critical for early cancer detection, monitoring minimal/measurable residual disease (MRD), and guiding precision oncology. Nevertheless, because of artifacts introduced during library preparation and...
19.
Singh R, Jeyaraju D, Voisin V, Hurren R, Xu C, Hawley J, et al.
Cell Stem Cell
. 2020 May;
26(6):926-937.e10.
PMID: 32416059
Leukemic stem cells (LSCs) rely on oxidative metabolism and are differentially sensitive to targeting mitochondrial pathways, which spares normal hematopoietic cells. A subset of mitochondrial proteins is folded in the...
20.
Sibai H, Chen R, Liu X, Falcone U, Schimmer A, Schuh A, et al.
Br J Haematol
. 2020 May;
191(5):748-754.
PMID: 32395867
Venous thromboembolism (VTE) is a well-known complication in adults receiving asparaginase (ASNase)-based intensification chemotherapy for acute lymphoblastic leukaemia (ALL). The optimal preventative strategy is unclear. Our objective is to determine...